C4 Therapeutics, Inc. (CCCC)
$
2.58
-0.07 (-2.71%)
Key metrics
Financial statements
Free cash flow per share
-1.2333
Market cap
153 Million
Price to sales ratio
4.4690
Debt to equity
0.3615
Current ratio
5.0551
Income quality
0.7834
Average inventory
0
ROE
-0.5391
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company that focuses on developing innovative therapeutic candidates aimed at degrading disease-causing proteins for the treatment of cancer, neurodegenerative disorders, and other illnesses. The cost of revenue for the company is $7,894,000.00 showcasing its production and operational expenses. With a revenue of $35,584,000.00 the company demonstrates its niche market focus and commitment to addressing unmet medical needs. The gross profit stands at $35,584,000.00 highlighting the company's profitability from core operations. Furthermore, the operating income ratio is -3.36 indicating the company's operational profitability margin. Additionally, the company earned an interest income of $14,429,000.00 showcasing its financial investments. Its lead product candidate, CFT7455, is an orally bioavailable MonoDAC degrader undergoing a Phase 1/2 trial, targeting IKZF1 and IKZF3 for treating multiple myeloma and non-Hodgkin lymphomas. C4 Therapeutics is also advancing other promising candidates, including CFT8634, CFT1946, and CFT8919, as well as earlier-stage programs targeting RET degraders for various cancers. The company benefits from strategic collaborations with F. Hoffmann-La Roche Ltd, Biogen MA, Inc., and Calico Life Sciences LLC. Founded in 2015, C4 Therapeutics is headquartered in Watertown, Massachusetts. The stock is affordable at $3.16 making it suitable for budget-conscious investors. Moreover, the stock has a high average trading volume of 2,044,812.00 indicating strong liquidity and interest among traders. With a market capitalization of $183,598,448.00 the company is classified as a small-cap player, reflecting its growth potential within the industry. It is a key player in the Biotechnology industry, contributing significantly to the overall market landscape. Additionally, C4 Therapeutics belongs to the Healthcare sector, where it drives innovation and growth. The company’s ongoing development programs position it well to impact the treatment landscape significantly, aligning with its strategic goals in the biopharmaceutical arena.
Is C4 Therapeutics, Inc. (CCCC) a good investment?
Investing in C4 Therapeutics, Inc. (CCCC) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C, with a Bullish outlook. Always conduct your own research before investing.
What is C4 Therapeutics, Inc. (CCCC)'s stock forecast?
Analysts predict C4 Therapeutics, Inc. stock to fluctuate between $1.09 (low) and $6.52 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is C4 Therapeutics, Inc.'s market capitalization?
As of 2025-10-29, C4 Therapeutics, Inc.'s market cap is $183,598,448, based on 71,162,189 outstanding shares.
How does C4 Therapeutics, Inc. compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, C4 Therapeutics, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy C4 Therapeutics, Inc. (CCCC) stock?
To buy C4 Therapeutics, Inc. (CCCC) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for CCCC. Place an order (Market, Limit, etc.).
What is the best time to invest in C4 Therapeutics, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
How did C4 Therapeutics, Inc. perform in the last earnings report?
Revenue: $35,584,000 | EPS: -$1.52 | Growth: -43.07%.
Where can I find C4 Therapeutics, Inc.'s investor relations reports?
Visit https://www.c4therapeutics.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for C4 Therapeutics, Inc.?
You can explore historical data from here
What is the all-time high and low for C4 Therapeutics, Inc. stock?
All-time high: $51.21 (2021-09-23) | All-time low: $1.06 (2023-12-06).
What are the key trends affecting C4 Therapeutics, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
globenewswire.com
$125 Million in Upfront Proceeds Expected to Fund Next Phase of Cemsidomide Multiple Myeloma Development Including Registrational Phase 2 Trial in Combination with Dexamethasone and Phase 1b Trial in Combination with Elranatamab
seekingalpha.com
C4 Therapeutics, Inc. - Special Call Company Participants Courtney Solberg - Senior Manager of Investor Relations Andrew Hirsch - CEO, President & Director Leonard M. J. Reyno - Chief Medical Officer Kendra Adams - CFO & Treasurer Conference Call Participants Sudan Loganathan - Stephens Inc., Research Division Binod Dhakal Bradley Canino - Guggenheim Securities, LLC, Research Division Etzer Darout - Barclays Bank PLC, Research Division Derek Archila - Wells Fargo Securities, LLC, Research Division Yifan Xu - Jefferies LLC, Research Division Presentation Operator Good day, and welcome to the C4 Therapeutics' Phase I trial data of cemsidomide in multiple myeloma presented at IMS 2025 Conference Call.
globenewswire.com
Cemsidomide in Combination With Dexamethasone Achieved a 50% Overall Response Rate (ORR) at the Highest Dose Level (100 µg) and a 40% ORR at the 75 µg Dose Level in a Heavily Pre-Treated Relapsed/Refractory Multiple Myeloma Patient Population
fool.com
C4 Therapeutics (CCCC 33.84%) was not only one of the better-performing healthcare stocks on Monday, it was one of the big winners on the market, period. The company seemed to have a rocket strapped to its back, as its share price blasted more than 34% higher after an analyst upgraded his recommendation.
seekingalpha.com
CCCC's valuation is unjustifiably low, trading at half its liquidity despite a promising pipeline and no imminent cash crisis. Lead candidate cemsidomide shows encouraging early efficacy and tolerability in heavily pretreated multiple myeloma patients, with key data readouts expected in Q3 2025. Cost controls and restructuring have extended CCCC's cash runway into 2027, reducing dilution risk and supporting ongoing development and partnerships.
zacks.com
C4 Therapeutics (CCCC) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
See all news
